CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
February 16, 2011

CalciMedica Appoints Steven L. Schoenfeld, MD, as Vice President, Clinical Development
June 23, 2010

CalciMedica Announces Issuance of US Patent No. 7,645,588, a Composition Patent Involving STIM1, a Key Component of the CRAC Channel
February 16, 2010

CalciMedica Achieves Milestone and Draws Down Second Tranche of $12 Million Series C Financing
December 15, 2009

CalciMedica Appoints Evelyn Graham to its Board of Directors
October 13, 2009

CalciMedica Exercises Option to Acquire Additional Intellectual Property from TorreyPines Therapeutics
October 13, 2008

CalciMedica Acquires Exclusive Rights to Novel Immune Signaling Targets for Treating Autoimmune Diseases from The CBR Institute
May 7, 2007

TorreyPines Therapeutics Transfers Intellectual Property and Compounds for Treating Autoimmune Diseases to CalciMedica
May 7, 2007